Literature DB >> 17465257

Prognostic significance of HER-2, p53 and Bcl-2 in patients with epithelial ovarian cancer.

Vassiliki Malamou-Mitsi1, Olga Crikoni, Eleni Timotheadou, Gerassimos Aravantinos, Eleni Vrettou, Niki Agnantis, George Fountzilas.   

Abstract

BACKGROUND: Several oncogenes and onco-suppressor genes have been implicated in epithelial ovarian carcinogenesis, but their clinical significance is not clear and conflicting data have been found in various studies. PATIENTS AND METHODS: The immunohistochemical expression of HER-2, p53 and Bcl-2 proteins was investigated in a cohort of 95 patients with advanced epithelial ovarian cancer (stages IIc-IV). These patients participated in a phase III randomized clinical trial and were treated either with paclitaxel/carboplatin, orpaclitaxel/carboplatin alternating with paclitaxel/cisplatin.
RESULTS: Positive immunostaining for HER-2, p53 and Bcl-2 proteins was found in 18%, 70.5% and 69.5% of the cases, respectively. In multivariate analysis, older patients (< 63 vs. > or = 63 years, p < 0.001), worse grade (I-II vs. III, p = 0.04) and p53 expression (negative vs. positive, p = 0.002) were significant prognostic factors independently associated with survival.
CONCLUSION: p53 status along with age and grade appear to be independent prognostic factors for survival in patients with epithelial ovarian cancer.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17465257

Source DB:  PubMed          Journal:  Anticancer Res        ISSN: 0250-7005            Impact factor:   2.480


  9 in total

Review 1.  Prognostic significance of several biomarkers in epithelial ovarian cancer: a meta-analysis of published studies.

Authors:  Linjuan Xu; Jing Cai; Qiang Yang; Hui Ding; Liying Wu; Tao Li; Zehua Wang
Journal:  J Cancer Res Clin Oncol       Date:  2013-04-18       Impact factor: 4.553

2.  S3-Guideline on Diagnostics, Therapy and Follow-up of Malignant Ovarian Tumours: Short version 1.0 - AWMF registration number: 032/035OL, June 2013.

Authors:  U Wagner; P Harter; F Hilpert; S Mahner; A Reuß; A du Bois; E Petru; W Meier; P Ortner; K König; K Lindel; D Grab; P Piso; O Ortmann; I Runnebaum; J Pfisterer; D Lüftner; N Frickhofen; F Grünwald; B O Maier; J Diebold; S Hauptmann; F Kommoss; G Emons; B Radeleff; M Gebhardt; N Arnold; G Calaminus; I Weisse; J Weis; J Sehouli; D Fink; A Burges; A Hasenburg; C Eggert
Journal:  Geburtshilfe Frauenheilkd       Date:  2013-09       Impact factor: 2.915

3.  Status of HER1 and HER2 in peritoneal, ovarian and colorectal endometriosis and ovarian endometrioid adenocarcinoma.

Authors:  C Uzan; E Darai; A Valent; O Graesslin; A Cortez; R Rouzier; P Vielh
Journal:  Virchows Arch       Date:  2009-03-18       Impact factor: 4.064

4.  Prognostic value of HER-2/neu expression in epithelial ovarian cancer: a meta-analysis.

Authors:  Yan Wang; Dong Wang; Mulan Ren
Journal:  Tumour Biol       Date:  2013-07-20

5.  MAD2 Expression in Ovarian Carcinoma: Different Expression Patterns and Levels among Various Types of Ovarian Carcinoma and Its Prognostic Significance in High-Grade Serous Carcinoma.

Authors:  Po Eun Park; Ji Yun Jeong; Sun Zoo Kim; Ji Young Park
Journal:  Korean J Pathol       Date:  2013-10-25

6.  The prognostic value of HER2 in ovarian cancer: A meta-analysis of observational studies.

Authors:  Hui Luo; Xiaohui Xu; Miaomiao Ye; Bo Sheng; Xueqiong Zhu
Journal:  PLoS One       Date:  2018-01-30       Impact factor: 3.240

7.  Prognostic value of HER-2/neu expression in epithelial ovarian cancer: a systematic review and meta-analysis.

Authors:  Kai Wang; Chenan Guan; Junhui Yu; Xiaoxiao Jin; Ling Sun; Lingzhi Zheng; Liang Xia; Yuquan Zhang
Journal:  Oncotarget       Date:  2017-09-06

8.  Modest effect of p53, EGFR and HER-2/neu on prognosis in epithelial ovarian cancer: a meta-analysis.

Authors:  P de Graeff; A P G Crijns; S de Jong; M Boezen; W J Post; E G E de Vries; A G J van der Zee; G H de Bock
Journal:  Br J Cancer       Date:  2009-06-09       Impact factor: 7.640

9.  Predictive and prognostic protein biomarkers in epithelial ovarian cancer: recommendation for future studies.

Authors:  Cécile Le Page; David G Huntsman; Diane M Provencher; Anne-Marie Mes-Masson
Journal:  Cancers (Basel)       Date:  2010-05-26       Impact factor: 6.639

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.